AKR1B10-IN-1, a powerful AKR1B10 (Aldo-Keto Reductase 1B10) inhibitor, demonstrates an IC50 value of 3.5 nM. This compound effectively curtails the proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells.
LX-4 is a selective activator of the p38 mitogen-activated protein kinase (MAPK) pathway. LX-4 de-represses a subset of endogenous genes repressed by DNA methylation.
MAO-B-IN-10 (compound 4f) is a highly potent and selective inhibitor of MAO-B (monoamine oxidase-B). It effectively penetrates the blood-brain barrier and exhibits an IC50 of 5.3 μM. This compound demonstrates the ability to inhibit self-mediated Aβ (amyloid β) aggregation by 58.2% and disaggregate it by 43.3%. Thus, MAO-B-IN-10 holds promise for Alzheimer's disease research [1].